A New Era in AMD Management: Treatments for Geographic Atrophy
Provider: Mivision
Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616
Activity Outline
Geographic atrophy (GA), a late form of age-related macular degeneration (AMD), until now has been untreatable, leading to progressive loss of central vision. In early 2023, the first treatment for GA, Pegcetacoplan (Syfovre, Apellis Pharmaceuticals), was approved in the United States and has been used in clinical practice for several months. In August, a second treatment, avacincaptad pegol (Izervay, Iveric Bio), also received approval in the US.
Other jurisdictions are expected to gain approval in the not too distant future. How do we ensure that we are in the best position to manage GA when treatments become available to slow vision loss? Longitudinal multi-modal imaging of the retina and upskilling to identify biomarkers influencing growth will help in the management of GA in this new era.
Learning Objectives
- Appreciate that management of geographic atrophy (GA) is about to fundamentally change as treatments become available
- Understand that the first treatments for GA will be given by frequent intravitreal injections, with the aim to slow disease progression, not stop or reverse the vision loss
- Realise the importance of imaging people with GA
- Be able to interpret signs of atrophy on optical coherence tomography (OCT)
Max CPD hours awarded: 1.5
Session Information
| Name |
|---|
| A New Era in AMD Management: Treatments for Geographic Atrophy |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 1 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.5 |